Hair transplants and hair loss treatments like oral Fin and Min are discussed, with some humor about public figures' hair. Missing a single day of these treatments typically has little impact, but longer gaps can affect results.
DUPA and retrograde alopecia may not be solely DHT-based, and a biopsy is crucial for accurate diagnosis and treatment. Treatments mentioned include dutasteride, oral minoxidil, pioglitazone, clobetasol, calcipotriol, ketoconazole, and doxycycline, depending on the specific condition.
Han Bio plans to start clinical trials for a new hair multiplication technology this year, which could significantly reduce the cost and time of hair transplantation. The technology uses a single hair strand to cultivate enough cells for 30,000 hair strands.
The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.
The conversation discusses using topical dutasteride with a dermapen for hair loss treatment. The user is deciding between liposomal and mesosomal formulations for this purpose.
User started Finasteride for hair loss and uses Toppik to cover bald spots. They wonder if Toppik's keratin fibers will block follicles and affect hair regrowth.
Hair loss without a white bulb may indicate mechanical damage, anagen effluvium, alopecia areata, or traction alopecia. Seeking a specialist is recommended, but access can be difficult in smaller areas.
Automatic-Law-3612's progress with hair loss treatments, including topical finasteride, topical dutasteride, minoxidil and pyrilutamide. They have been using these products for two weeks and noticed baby hairs in their temples getting longer.
A user discusses a company, Roots by Genetic Arts, that offers a genetic test for hair loss to create personalized treatments, and is curious about its legitimacy and the science behind it. The company tests 16 genes related to hair loss and compounds a topical treatment based on the results.
A user shared an 8.5-month update on their hair transplant of 1064 grafts done by Dr. Kaan Pekiner in Ankara, Turkey, costing $3500. They are also using finasteride 2.25 mg weekly and have reduced shampoo use.
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
A user shared their positive experience with MoriTint, a Korean scalp micro pigmentation technique that enhances the appearance of hair density without being permanent. They now offer this service in Los Angeles and emphasize its benefits for those with thinning hair, while clarifying it is not suitable for those with significant hair loss or baldness.
Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.
The conversation discusses using finasteride, dutasteride, minoxidil, and RU58841, along with a 10,000 graft hair transplant, to prevent magpies from targeting bald men. The title humorously references an eight-year-old's survey on magpies swooping bald men.
A user is starting a topical finasteride treatment for diffuse patterned alopecia, having previously used minoxidil without success. They are cautious about side effects and have chosen topical over oral finasteride, while also using Nizoral and biotin in their routine.
Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.
L'Oreal is working on hair cloning, with multiple companies using similar techniques, making hair cloning likely by 2030. The conversation expresses optimism about the progress and potential affordability of hair cloning solutions.
A user shared their experience with two hair transplants in Istanbul, highlighting the importance of choosing clinics with a low doctor-to-patient ratio, ISHRS membership, thorough consultations, and reliable aftercare. They emphasized the significance of PRP shots post-procedure and advised careful selection of clinics, especially for crown procedures, due to limited donor area opportunities.
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
The post discusses a theory that hair regrowth after transplant is due to the angiogenesis process (new blood vessels forming), not because the transplanted hair is unaffected by DHT. The responses highlight the established belief in 'donor dominance' (the importance of the hair's origin in transplantation) and skepticism about the new theory.
The conversation is about people with advanced hair loss (Norwood 6 or 7) who have seen significant hair regrowth using treatments like finasteride, minoxidil, microneedling, and RU58841. Nine cases were collected to motivate others to try these treatments despite advanced hair loss.
The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.
A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.
The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.
Reincarnation humorously suggested as a hair restoration method, with exaggerated and satirical discussions on finasteride use. The conversation includes jokes about side effects and the absurdity of extreme measures for hair loss.
The conversation discusses the use of Finastopic, a carrier for finasteride solutions by Isdin, and compares it to a standard propylene glycol (PG) solution. The user was prescribed a 1% finasteride solution using Finastopic and has been using a self-compounded 0.025% topical finasteride with minoxidil.
The post and conversation discuss the unpredictable nature of diffuse thinning, a type of hair loss. Users share personal experiences, with some mentioning treatments like oral finasteride and toppik, and the need for patience with these treatments.
The user is using a hair loss treatment regimen that includes applying various topical solutions and taking oral medication. They are mixing their topical treatments to save time but are concerned about the effectiveness of the treatments when combined and stored.
A recent discovery in hair cloning identified a previously unknown cell type essential for hair follicle growth, which could potentially make lab-grown hair viable if translated to humans. However, skepticism remains due to past delays and the challenges of replicating results in humans and making the process affordable.